# A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

> **NCT00735475** · PHASE4 · COMPLETED · sponsor: **Seqirus** · enrollment: 1268 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** CSL Limited Influenza Virus Vaccine (Afluria®)
- **BIOLOGICAL:** US Licensed Influenza Virus Vaccine (Fluzone®)

## Key facts

- **NCT ID:** NCT00735475
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-01
- **Final completion:** 2009-06
- **Target enrollment:** 1268 (ACTUAL)
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735475, "A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00735475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*